03-Jan-2003 - Albany Molecular Research, Inc. (AMRI)

AMRI Acquires Majority Interest in Organichem Corporation

Albany Molecular Research, Inc. announced that it has exercised its conversion option with respect to $15 million of Organichem Corporation subordinated debentures. The conversion into additional shares of Organichem common stock took effect on January 1, 2003, and increases AMRI's ownership in Organichem from 39.2% to 75%. "The debenture conversion is a step towards AMRI's ultimate purchase of Organichem, which we expect to occur within the next few months," said AMRI Chairman and Chief Executive Officer Thomas E. D'Ambra, Ph.D. "Ownership of Organichem will provide AMRI customers with a one-stop, continuous range of resources from bench-scale synthesis to commercial cGMP manufacturing." Organichem Corporation was founded in 1999 through a management led buyout of the Nycomed Amersham plc chemical manufacturing facility in Rensselaer, New York. AMRI was a founding investor in the formation of Organichem which was announced on December 21, 1999. AMRI's investment in Organichem included a $15 million equity investment for a 37.5% ownership and $15 million in debentures, which could be converted into additional equity in Organichem after three years. The December 1999 investment agreement with Organichem also gave AMRI the option to purchase the remaining Organichem shares subsequent to the completion of Organichem's 2002 audited financial statements. AMRI has previously communicated its intention to exercise the purchase option. The purchase price is to be determined based on Organichem's financial performance in the year 2002. At this time, it is estimated that the purchase price will be approximately $30 million. AMRI will begin consolidating Organichem's operating results effective January 1, 2003. In its previous status as a minority shareholder, AMRI only included its proportionate share of Organichem's net income in its income statement as equity in income of unconsolidated affiliates.

Facts, background information, dossiers
  • Albany Molecular Research
More about Albany Molecular Research
  • News

    AMRI to Close Holywell, U.K. API Manufacturing Facility

    AMRI announced that it has decided to close its Holywell, U.K. facility following a consultation process with employee representatives. The Holywell site provides chemical development services and small- and large scale-manufacturing services of active pharmaceutical ingredients (API) and i ... more

    AMRI Opens New Research Facility in Budapest, Hungary

    AMRI announced that it has finished the construction of a new state-of-the-art chemistry R&D facility in Budapest, Hungary. The successful completion and move into 32,300 square feet (3,000 square meters) of laboratory and administrative space marks a significant milestone in the company’s ... more

    AMRI Names Senior Director, Analytical and Quality Services

    AMRI announced that Junan Guo, Ph.D. has joined the company as senior director, analytical and quality services. Dr. Guo fills the role vacated by Dr. Steven Hagen, who was promoted to vice president of pharmaceutical development and manufacturing in September 2008. Dr. Guo will oversee a ... more

  • Companies

    Albany Molecular Research, Inc. (AMRI)

    Founded in 1991 as Albany Molecular Research, Inc., AMRI provides scientific services, products and technologies focused on improving the quality of life. The company has steadily evolved, with global facilities now in the United States, Europe and Asia. Its 1,200+ employees have the expe ... more